Dopaminergic Drugs in Cardiovascular Emergencies
Drugs acting at dopamine (DA) receptors provide an important therapeutic approach in the treatment of various cardiovascular emergencies [1–3]. Peripheral dopamine receptors are classified into two distinct subtypes, namely DA-1 and DA-2 [1–3]. Whereas DA, in addition to stimulating both DA-1 and DA-2 receptors, also activates α- and β-adrenoceptors, there are compounds available which preferentially activate either DA-1 and/or DA-2 receptors and do not stimulate a- and β-adrenoceptors. The major cardiovascular consequence following stimulation of DA receptors include decreases in cardiac afterload or peripheral vascular resistance, increases in cardiac index, mesenteric and renal blood flows as well as natriuresis and diuresis. The dopaminergic drugs currently available for the treatment of cardiovascular emergencies include dopamine, fenoldopam and dopexamine.
KeywordsDopamine Luminal Catecholamine Amphotericin Inositol
Unable to display preview. Download preview PDF.
- 1.Lokhandwala MF, Hegde SS (1991) Cardiovascular pharmacology of adrenergic and dopaminergic receptors: Therapeutic significance in congestive heart failure. Am J Med 90 (Suppl 5B): 5–9Google Scholar
- 2.Chen CJ, Lokhandwala MF (1992) Dopamine receptor agonists in cardiovascular pharmacotherapy. Ind J Pharmacol 24: 72–81Google Scholar
- 3.Lokhandwala MF, Chen CJ (1993) Peripheral dopamine receptors. In: Niznik HB (ed) Dopamine receptor function and pharmacology. Marcel Dekker, New York, pp 89–92Google Scholar
- 12.Linder A (1983) Synergism of dopamine and furosemide in diuretic-resistant oliguric acute renal failure. Nephron 37: 39–42Google Scholar
- 13.Lokhandwala MF (1991) Effects of dopamine receptor agonists on cardiovascular and renal function. In: Vincent JL (ed) Update in intensive care and emergency medicine, Vol 14. Springer-Verlag, Berlin, pp 74–80Google Scholar
- 14.Nichols AJ, Koster PF, Brooks DP, Ruffolo RR Jr (1992) Effect of fenoldopam on the acute and subacute nephrotoxicity produced by amphotericin B in the dog. J Pharmacol Exp Therapy 260: 269–274Google Scholar
- 17.Vincent JL (ed) (1991) Towards improving vital organ function: Assessing the role of dopexamine hydrochloride in intensive care medicine. Clin Intensive Care 2 (Suppl): 5–54Google Scholar
- 18.Boyd O, Bennett ED (1992) Effects of dopexamine hydrochloride in a porcine sepsis model and in high-risk peri-operative surgical patients. Clin Intensive Care 3 (Suppl): 32–36Google Scholar
- 22.Chintala MS, Moore RJ, Lokhandwala MF, Jandhyala BS (1993) Evaluation of the effects of dopexamine, a novel DA-1 receptor and β2-adrenoceptor agonist, on cardiac function and splanchnic circulation in a canine model of hemorrhagic shock. Naunyn-Schmiedeberg’s Arch Pharmacol 347: 396–400CrossRefGoogle Scholar